BMRN vs WULF · P/E 40, rev $1.76B vs rev $78.8M
Biomarin Pharmaceutical Inc (BMRN) versus Terawulf Inc (WULF) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Terawulf Inc (WULF) is a capital markets company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported WULF revenue for 2026-06-30 was $78.8M. Net income was -$1.37B. WULF currently screens at market cap $2.05B.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. WULF currently screens at market cap $2.05B.
Not investment advice. Open the BMRN and WULF stock pages for the full models.
Not investment advice.